Navigation Links
New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
Date:5/19/2009

ted that patients with schizophrenia in the Veterans Affairs (VA) system who also suffered from other medical or psychiatric illnesses had fewer and shorter-duration psychiatric hospitalizations after the initiation of RISPERDAL(R) CONSTA(R).

This analysis identified all VA patients with schizophrenia who began RISPERDAL(R) CONSTA(R) between October 1, 2005 and September 30, 2006 and received at least four (total) injections (N=924). The analysis compared changes in health services use between 12 months prior to and 12 months after initiation of RISPERDAL(R) CONSTA(R). Results showed that between the pre- and post- RISPERDAL(R) CONSTA(R) initiation periods, the mean number of psychiatric hospitalizations and length of stay significantly decreased for patients with three or more concurrent illnesses, while psychiatric-related outpatient visits increased.(4)

"The results of this analysis suggest that long-acting therapy may reduce the need for repeated hospitalizations and improve everyday psychiatric follow-up among patients with complex medical histories," continued Dirani.

A limitation of these two studies is that they did not compare RISPERDAL(R) CONSTA(R) to placebo or other treatments.

The studies were presented and sponsored by Ortho-McNeil Janssen ScientificAffairs.

About Schizophrenia

According to the National Institute of Mental Health, an estimated one percent of the U.S. population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others and distinguish between reality and imagination. It typically develops in adolescence or the early 20s, although symptoms may not become immediately obvious.

About RISPERDAL(R) CONSTA(R)

RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) is a long-acting injectable atypical antipsychotic therapy used for the treatment of
'/>"/>

SOURCE Janssen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Justice Department to Hold Media Event to Demonstrate New Database for Matching Unidentified Remains and Missing Persons Information
4. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
5. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
6. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
7. STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their Good Cents
8. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery
11. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 T.E.N., ... relationship-marketing firm, honored finalists and winners Wednesday evening, ... Forum and Awards Gala at the Westin St. ... director of information security for the BlackLine Systems, ... the Year Award winner for the ISE® West ...
(Date:7/31/2014)... Amy Norton HealthDay ... Babies born with so-called "bubble boy" disease can often be ... -- but early treatment is critical, a new study finds. ... known, actually refers to a group of rare genetic disorders ... at high risk of severe infections. The term "bubble ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... to reach $702m by 2020, increasing slowly ... market will be driven by: the rising ... incurred by government agencies, such as Medicare, ... adoption of innovative technologies such as flow ...
(Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
Breaking Medicine News(10 mins):Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 5Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2
... to be Delayed, CAMBRIDGE, Mass., Nov. 13 ... has received a letter from the U.S.,Food and Drug ... for Synvisc-One(TM) in the United,States. The company now expects ... be delayed in the U.S. until at least the,second ...
... to avoid may offer protection , TUESDAY, Nov. 13 (HealthDay ... meats may help improve the chances of surviving a heart ... of a preliminary study in the Nov. 12 online edition ... . , Researchers found that mice fed extra nitrite ...
... house,abandoned older pets, who spend their last days watching ... kittens. November is Adopt-a-Senior-Pet Month and is dedicated ... and the fulfillment they can bring to the,right owner. ... these animals have been,surrendered," said Brent Hinton, former Kentucky ...
... water work,well for simple cleaning, they won,t do the ... illness. Something stronger must be used. U.S. Nonwovens ... this pressing problem. Rediwipes are proven to kill,99.9 percent ... "The first cardinal rule of safe food preparation in ...
... Inc.,(Nasdaq: CLRT ), a premier technology and ... today announced,that it was ranked #19 on Deloitte,s ... was also named to Deloitte,s 2007 Technology Fast ... Fast 50 is a ranking of the 50,fastest ...
... - No Human Vaccine Currently Exists Against the ... Deaths in the US so far in 2007;,Collaboration Aims ... as Rapidly as Possible Acambis plc (Acambis) (LSE: ... has signed an exclusive global,collaboration agreement with Sanofi Pasteur, ...
Cached Medicine News:Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 2Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 3Health News:Nitrite, Nitrate-Rich Foods Boost Heart Attack Outcomes 2Health News:Old Dogs Can Learn New Tricks 2Health News:Disinfecting Rediwipes(TM) Launch Targets E. coli and Salmonella 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 3Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 4Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 5Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 2Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 3Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 4
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
(Date:7/30/2014)... -- CryoLife, Inc. (NYSE: CRY), a leading medical device ... surgery, announced today that its Board of Directors has ... 2014 of $0.03 per share of common stock outstanding.  ... be paid on September 19, 2014 to all common ... ex-dividend date for the quarterly dividend is September 10, ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
Complete cytology platform....
... is the first in portability and performance. CTU ... need a flexible, portable system with the state-of-the-art features ... easily to an "E" size tank and has an ... where it is needed.,The CTU Travel Case allows you ...
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... Total GHb Program separates ... hemoglobin regardless of phenotype ... Schiff Base. Patient results ... DCCT reference to ensure ...
Medicine Products: